TABLE 4.

Clinical outcomes of patients treated with STN‐DBS

	BSD‐PD (n = 13)	PD (n = 27)
Gender n males (%)	5 (38.46)	13 (48.15)
Age at onset of PD, mean ± SD	43.67 ± 7.66	44.30 ± 7.99
Disease duration, mean ± SD	17.50 ± 5.66	16.81 ± 5.23
Age at STN‐DBS, mean ± SD	60.33 ± 7.05	61.22 ± 5.20
CGI‐I patient, mean ± SD	4.42 ± 0.67	1.52 ± 0.58
CGI‐I rater, mean ± SD	1.33 ± 0.49	1.26 ± 0.45

	Before	After	Before	After
UPDRS total, mean ± SD	53.08 ± 11.41	17.58 ± 4.72	52.26 ± 10.56	18.93 ± 4.60
UPDRS 32–33, mean ± SD	6.67 ± 1.37	1.33 ± 0.78	6.70 ± 1.14	1.37 ± 0.74
UPDRS 36–39, mean ± SD	6.17 ± 0.72	1.00 ± 0.85	6.04 ± 0.81	0.93 ± 0.78
LEDD, mean ± SD	834.17 ± 90.60	354.17 ± 96.43	820.74 ± 98.52	377.04 ± 62.13
PDQ‐8, mean ± SD	28.83 ± 2.04	24.00 ± 3.20 a	28.67 ± 1.83	13.41 ± 2.08
CGI‐S, mean ± SD	5.83 ± 0.58	2.25 ± 0.45	5.81 ± 0.83	2.30 ± 0.47

^a Notice that the only item not showing significant improvement after STN‐DBS is PDQ‐8 in the 13 BSD‐PD patients. P < 0.0001 in all other comparisons.

Abbreviations: BSD‐PD, bipolar spectrum disorder‐Parkinson's disease; STN‐DBS, subthalamic nucleus deep brain stimulation; CGI, Clinical Global Impression; CGI‐S, Clinical Global Impression‐severity of disease; CGI‐I, Clinical Global Impression‐improvement; SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating Scale: items 32–33, dyskinesias; items 36–39, off‐status; LEDD, l‐dopa equivalent daily dose; PDQ‐8, Parkinson's Disease Questionnaire‐8.